Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna.
Department of Biomedical Imaging and Image- Guided Therapy.
Int J Gynecol Cancer. 2018 Jul;28(6):1196-1202. doi: 10.1097/IGC.0000000000001291.
Recent data support the use of pembrolizumab in cervical cancer. The aim of this study was to investigate pembrolizumab in heavily pretreated patients with recurrent cervical cancer.
Data from consecutive patients treated with pembrolizumab at a single academic institution were assessed. Programmed cell death ligand 1 (PD-L1) status and microsatellite instability were assessed from tumor samples. Irrespective of PD-L1 expression status, pembrolizumab was administered at fixed dose of 200 mg intravenously every 3 weeks. Treatment response was evaluated by computed tomography, using iRECIST (2017) criteria. Descriptive statistics were performed. Results from previous publications were summarized.
In total, 11 heavily pretreated patients with recurrent cervical cancer received pembrolizumab. Of these, 2 (18%) patients showed partial response and 2 (18%) patients showed disease stabilization on computed tomography, resulting in a clinical benefit rate of 36%. These 4 patients are still on treatment and durable antitumor activity of up to 52 weeks was observed. Treatment was generally well tolerated with 1 patient showing dose-limiting toxicity. Median overall survival was 26 (3-53) weeks, and a 6-month overall survival rate of 65% was observed. Of the 5 patients with high PD-L1 expression, 3 showed response to treatment.
Pembrolizumab shows promising activity in heavily pretreated patients with recurrent cervical cancer in a real-life clinical setting. Treatment was generally well tolerated, and adverse effects were manageable. Growing evidence supports the use of pembrolizumab in this group of patients.
最近的数据支持在宫颈癌中使用派姆单抗。本研究旨在研究在复发性宫颈癌中大量预处理的患者中使用派姆单抗的情况。
评估了单所学术机构中连续接受派姆单抗治疗的患者的数据。评估了肿瘤样本中的程序性死亡配体 1（PD-L1）状态和微卫星不稳定性。无论 PD-L1 表达状态如何，均以 200mg 固定剂量静脉内每 3 周给予派姆单抗。使用 iRECIST（2017）标准通过计算机断层扫描评估治疗反应。进行描述性统计。总结了以前出版物的结果。
共有 11 名复发性宫颈癌大量预处理的患者接受了派姆单抗治疗。其中，2 名（18%）患者的计算机断层扫描显示部分缓解，2 名（18%）患者显示疾病稳定，临床获益率为 36%。这 4 名患者仍在接受治疗，观察到长达 52 周的持久抗肿瘤活性。治疗总体耐受良好，1 名患者出现剂量限制毒性。中位总生存期为 26（3-53）周，6 个月总生存率为 65%。5 名高 PD-L1 表达的患者中，有 3 名对治疗有反应。
派姆单抗在真实临床环境中对复发性宫颈癌的大量预处理患者显示出有前景的活性。治疗总体耐受良好，不良反应可管理。越来越多的证据支持在这组患者中使用派姆单抗。
